Study to Assess the Safety and Plasma Concentration of YM178 OCAS Tablet (Mirabegron) in Healthy Chinese Volunteers
PHASE1CompletedINTERVENTIONAL
Enrollment
24
Participants
Timeline
Start Date
May 31, 2012
Primary Completion Date
August 31, 2012
Study Completion Date
August 31, 2012
Conditions
Healthy Chinese Volunteers
Interventions
DRUG
YM178
oral
Trial Locations (1)
Unknown
Shanghai
All Listed Sponsors
lead
Astellas Pharma China, Inc.
INDUSTRY
NCT01720212 - Study to Assess the Safety and Plasma Concentration of YM178 OCAS Tablet (Mirabegron) in Healthy Chinese Volunteers | Biotech Hunter | Biotech Hunter